ライフサイエンスコーパス: third trimester

1 nd trimester, and 29% after infection in the third trimester).

2 wice during her pregnancy (in the second and third trimesters).

3 en, with the lowest risk reported during the third trimester.

4 trimester and to syncytiotrophoblasts in the third trimester.

5 s pregnancy progresses from the first to the third trimester.

6 pling, and with lower levels of HDL-C in the third trimester.

7 n newborns exposed to natalizumab during the third trimester.

8 2 y old and 20.9% of pregnant women in their third trimester.

9 ester (29.2%) and much higher (95.3%) in the third trimester.

10 as well as lower levels of HDL-C during the third trimester.

11 cond trimesters of pregnancy compared to the third trimester.

12 ance index and fetal growth were measured in third trimester.

13 74 g less (95% CI, -140 to -8 g) during the third trimester.

14 ompared to women screened and treated in the third trimester.

15 ts on lung epithelial cell maturation in the third trimester.

16 duled antenatal care visit in the second and third trimester.

17 9.1% during the second and 15.7% during the third trimester.

18 1%) were pregnant; 73 (89%) in the second or third trimester.

19 e sample collected from 319 women during the third trimester.

20 regnancy, which peaked in the middle to late third trimester.

21 te of transmethylation was higher during the third trimester.

22 enstrual cycle and modestly increased in the third trimester.

23 vels in normal pregnant women throughout the third trimester.

24 subsequent GPCMV challenge during the early third trimester.

25 in the second trimester, and 2 (8.3%) in the third trimester.

26 well as maternal blood FT4 concentrations at third trimester.

27 in the second trimester, and 5.1E-03 in the third trimester.

28 verall, decreasing further at the end of the third trimester.

29 vitamin B-12 decrease from the first to the third trimester.

30 tal brain injury acquired due to ZIKV in the third trimester.

31 ter, 4 in the second trimester, and 1 in the third trimester.

32 ation of all pregnant women in the second or third trimester.

33 formations but is feasible in the second and third trimesters.

34 r and greater than 3 mIU/L in the second and third trimesters.

35 ance indices were assessed in the second and third trimesters.

36 ic recommendations in the first, second, and third trimesters.

37 ron than did pregnant women in the second or third trimesters.

38 A enzyme in plaque samples at the second and third trimesters.

39 o Zika virus infection only in the second or third trimesters.

40 962 mothers were vaccinated in the second or third trimesters.

41 concentrations are measured in the second or third trimesters.

42 ricity index decreased from the first to the third trimester (1.92+/-0.17 versus 1.71+/-0.17) and ret

43 loma; P = 0.013), initiation of HAART in the third trimester (23.9% vs. 12.3% and 8.6% in the second

44 Serial first- (11-14 weeks) and third-trimester (30-34 weeks) serum samples were analyze

45 clampsia incidence at trial entry and in the third trimester (32-38 weeks) were studied.

46 , and having the first prenatal visit in the third trimester (33.3% vs. 14.3% and 10.5% in the second

47 e or four scheduled visits in the second and third trimester, 4 to 6 wk apart.

48 h higher LV stroke work was noted toward the third trimester (5.9+/-1.1 versus 5.3+/-1.0 Newton meter

49 he first trimester and 6644 in the second or third trimester]), 660 (330 exposed) were included in pr

50 -2.2] when the wildfire occurred during the third trimester, 9.7 g lower when it occurred during the

51 systolic BP in the offspring at 7 y of age (third trimester, age- and sex-adjusted: beta = -1.09; 95

52 Recently, we showed that third trimester alcohol exposure leads to a persistent d

53 a period of time commensurate with the human third trimester, also show deficits in classical eyeblin

54 harmacokinetic profiles performed during the third trimester and >/=2 weeks after delivery.

55 al diabetes mellitus who were exposed in the third trimester and 1.02 (95% confidence interval: 1.01,

56 and incidence of BV at both time points (ie, third trimester and 3 mo postpartum) by 30-40% compared

57 oad declines of at least 1 log10 between the third trimester and 3-mo postpartum exhibited HCV-specif

58 aemoglobin concentration measured during the third trimester and after delivery.

59 Maternal RSV antibody titers in the third trimester and at birth were strongly correlated (R

60 We screened pregnant women in their second/third trimester and at delivery for LTBI using the tuber

61 harmacokinetic sampling was performed in the third trimester and at least 2 weeks postpartum.

62 Mothers during the third trimester and children at ages 3, 5, and 7 years p

63 nce maternal-infant attachment, began in the third trimester and continued until 6 mo postpartum.

64 A and PC:PE ratios, in pregnant women in the third trimester and nonpregnant women.

65 harmacokinetic profiles were obtained in the third trimester and postpartum along with cord and mater

66 .0 g for exposures in the first, second, and third trimesters and for the total pregnancy, respective

67 .4 g for exposures in the first, second, and third trimesters and for the total pregnancy, respective

68 acental resistance indices in the second and third trimesters and persistence in the highest tertile

69 ed from pregnant women during the second and third trimesters and their children at 1 and 2 years of

70 ant concentrations in the first, second, and third trimesters and throughout the entire pregnancy.

71 arbon monoxide during the first, second, and third trimesters and total pregnancy were 1.005 (95% CI:

72 nal plasma samples pooled from the first and third trimesters and urine samples from children at age

73 n the first trimester than in the second and third trimesters and was significantly lower than that i

74 Third-trimester and childhood BC exposures were associat

75 e-time survival models were used to estimate third-trimester and total pregnancy associations.

76 ases of botulism during pregnancy (11 in the third trimester) and 1 case during the postpartum period

77 oid hormones for 285 pregnant women in their third trimester, and also measured cord serum thyroid ho

78 ients (89 of 94 [95%]) were in the second or third trimester, and approximately one third (32 of 93 [

79 ained during the first trimester, during the third trimester, and at delivery.

80 an-American and Dominican women during their third trimester, and from their children at ages 3 and 5

81 Energy intake decreased in the third trimester, and most women did not meet the nationa

82 hocardiograms in the first trimester, in the third trimester, and postpartum.

83 osure estimates in the entire pregnancy, the third trimester, and the last month of pregnancy.

84 .5 in the first trimester, second trimester, third trimester, and whole pregnancy were 1.07 (95% conf

85 acental resistance indices in the second and third trimesters are associated with increased risks of

86 ous abortion (organogenesis), and the second/third trimesters are the time windows of interest for SG

87 f universal ultrasonic fetal biometry in the third trimester as a screening test for small-for-gestat

88 clinically indicated ultrasonography in the third trimester as per routine clinical care and these r

89 sed odds per interquartile-range increase in third-trimester benzene, toluene, ethyl benzene, and xyl

90 trient status was assessed by measurement of third trimester blood biomarkers.

91 race/ethnicity, socioeconomic position, and third-trimester BP; and time trend.

92 ) ABCB1, TLR-3, and TLR-4 mRNA levels in the third trimester but not first trimester.

93 eased prenatal PAH exposure (measured in the third trimester but thought to index exposure for all of

94 fadoxine-pyrimethamine during the second and third trimesters, but noted the importance of a cost-eff

95 restricted invariant NKT (iNKT) cells in the third trimester by administration of alpha-galactosylcer

96 hazard ratios for tertiary amine use in the third trimester by increasing tertiles of nitrite intake

97 utero rates of calcium accretion during the third trimester cannot be readily achieved.

98 n decrease in exposure to raltegravir during third trimester compared to postpartum is not considered

99 nce of hepatic oxidative stress early in the third trimester, consistent with the development of nona

100 exposures in a logistic mixed model, and the third-trimester cumulative exposures in a discrete time

101 D4(+) and CD8(+) T cells obtained from human third trimester decidua and demonstrated that decidual C

102 he prevalence nor the incidence of BV in the third trimester differed by supplement group.

103 iated with gestational hyperglycaemia in the third trimester disrupt regulatory element activity and

104 ubated with 5.25 g/kg/day ethanol during the third trimester equivalent (postnatal days [PDs] 4-9).

105 exposed to 5.25 g/kg/day ethanol during the third trimester equivalent brain growth spurt (postnatal

106 thanol (EtOH), including exposure during the third trimester-equivalent (i.e., neonatal period in rat

107 ntation is effective when administered after third-trimester-equivalent ethanol treatment.

108 In the third trimester expectant mothers wore personal air samp

109 No association was found between second- or third-trimester exposure to intranasal triamcinolone and

110 ll size for gestational age after second- or third-trimester exposure, 13,284 (6642 exposed) were inc

111 n 302 of 6543 infants (4.6%) with second- or third-trimester exposure, compared with 295 of 6366 unex

112 n 641 of 6642 infants (9.7%) with second- or third-trimester exposure, compared with 657 of 6642 unex

113 posure was divided into first-, second-, and third-trimester exposure.

114 ith a 60% increased risk for ASD, higher for third-trimester exposures (OR = 2.0; 95% CI: 1.1, 3.6),

115 Second- and third-trimester exposures increased the odds of bilatera

116 creening of nulliparous women with universal third trimester fetal biometry roughly tripled detection

117 184 fetuses from 2 LQT1 founder populations, third trimester fetal heart rate discriminated between f

118 We investigate third trimester fetal heart rate, routinely recorded wit

119 arterioles were harvested from the brains of third trimester fetal sheep previously exposed in the se

120 Second- and third-trimester fetal growth characteristics (head circu

121 ns in the lower quartiles had offspring with third-trimester fetal growth restriction, leading to a s

122 Higher third trimester feto-placental vascular resistance, but

123 Our analyses of third-trimester fetuses exposed to single daily oral dos

124 spontaneous abortions and during the second/third trimesters for small-for-gestational age (SGA) new

125 ssed in multivariate models between maternal third trimester glucose tolerance and indexes of body co

126 stillbirth is defined as fetal death in the third trimester (>/=1000 g birthweight or >/=28 complete

127 influence of second-trimester (GW 13-25) vs third-trimester (>/=GW 26) tetanus-diphtheria-acellular

128 omen who were reportedly infected during the third trimester had given birth, and no infants with app

129 antiviral therapy for pregnant women in the third trimester has been shown to be highly effective in

130 d, with changes in the microbiome during the third trimester having metabolic consequences for the mo

131 ; and hemoglobin decline over the second and third trimesters (hazard ratio, 1.7; confidence interval

132 al first- (sphingomyelin C18:1 and urea) and third-trimester (hexose and citrate) metabolite screenin

133 These findings indicate that elevated third-trimester homocysteine levels may be a risk factor

134 Elevated third-trimester homocysteine levels may elevate schizoph

135 model that tested for a threshold effect of third-trimester homocysteine levels, an elevated homocys

136 ates reached 80% vs 55% following second- vs third-trimester immunization (adjusted odds ratio, 3.7 [

137 ti-FHA GMCs were higher following second- vs third-trimester immunization (PT: 57.1 EU/mL [95% confid

138 The adjusted GMC ratios after second- vs third-trimester immunization differed significantly (PT:

139 Maternal immunization during the third trimester, immunization of other infant contacts,

140 tal day 7 (P7), which is comparable with the third trimester in human pregnancy, induces synaptic dys

141 g/day of alcohol on postnatal days (PD) 4-9 (third trimester in humans), in a binge-like manner.

142 Although the HELLP symptoms occur in the third trimester in the mother, the origin of the disease

143 urine samples collected during the first and third trimesters in pregnant women participating in the

144 prevalent in pregnant women in the second or third trimesters, in Mexican American pregnant women, in

145 euptake inhibitors, during the second and/or third trimester increases the risk of ASD in children, e

146 Administration of alpha-GalCer in the third trimester induced an increase in the activation of

147 ytopenia or thrombocytopenic bleeding in the third trimester, intravenous immunoglobulin is an approp

148 6], with the lowest rate reported during the third trimester (IRR, 0.47; 95% CI, 0.35-0.64) for all a

149 Compared with the third trimester, lamotrigine serum concentration increas

150 rent wheezing through 3 years of age and (2) third trimester maternal 25-hydroxyvitamin D levels.

151 nine (nicotine metabolite) were assayed from third trimester maternal sera.

152 ders, hemolytic disease, multiple gestation, third-trimester maternal infection, chorioamnionitis, to

153 1959-1965; exposure levels were measured in third-trimester maternal serum that was collected before

154 ed PFOA and four long-chain PFCAs (ng/mL) in third-trimester maternal serum; infant weight (kg), leng

155 sured phthalate metabolite concentrations in third-trimester maternal urine in a cohort of women enro

156 study demonstrates that second- rather than third-trimester maternal vaccination results in higher b

157 illness occurring almost exclusively in the third trimester; microvesicular fatty infiltration of he

158 = 1), the second trimester (n = 2), and the third trimester (n = 3).

159 301 women during second trimester (n = 39), third trimester (n = 40), and preterm labor with intact

160 A cohort of pregnant women in their early third trimester (n = 81) were prospectively enrolled for

161 of miniature pigs (second trimester, n = 2; third trimester, n = 2).

162 , to our knowledge, comprehensive data about third-trimester natalizumab exposure are scant.

163 Deficits in maternal O(2) transport in third trimester normal pregnancy are unlikely to be caus

164 Severe flares in the second and third trimesters occurred in 2.5% and 3.0%, respectively

165 hat the number of BANA-infected sites in the third trimester (odds ratio [OR]: 5.89; 95% confidence i

166 pertussis (Tdap) vaccine at the start of the third trimester of each pregnancy to optimize transplace

167 ily feed by mouth at the equivalent age of a third trimester of gestation as the majority of their te

168 ate that morphine exposure equivalent to the third trimester of gestation produced prolonged pain hyp

169 Placental triglyceride oscillations in the third trimester of human pregnancy are lost in large-for

170 he neonatal period that is equivalent to the third trimester of human pregnancy, are potential treatm

171 te of oestradiol that is elevated during the third trimester of normal human pregnancy.

172 rkers in plasma or urine from women in their third trimester of pregnancy (n = 200).

173 wo-thirds in the rate of relapses during the third trimester of pregnancy and a significant increase

174 on was stronger when BPA was measured in the third trimester of pregnancy and decreased with time bet

175 D-deficient diet for female mice during the third trimester of pregnancy and lactation.

176 eased maternal glucose concentrations in the third trimester of pregnancy and placental IGF-II conten

177 of the cerebral cortex would continue in the third trimester of pregnancy and that preterm birth woul

178 take inhibitor (SSRI) fluoxetine late in the third trimester of pregnancy and the risk of PPHN in the

179 wore a wrist actigraph for 7 days during the third trimester of pregnancy and within three months pos

180 itamin D levels of 30 ng/mL or higher by the third trimester of pregnancy compared with 133 of 391 (3

181 he use of 2800 IU/d of vitamin D3 during the third trimester of pregnancy compared with 400 IU/d did

182 as measured in spot urine samples during the third trimester of pregnancy from 407 African-American a

183 Here we show that the fetus in the third trimester of pregnancy is more likely to engage wi

184 nal infection with the Zika virus during the third trimester of pregnancy is not linked to structural

185 uals with ileal Crohn's disease and in their third trimester of pregnancy often resembled infants fro

186 ozygous alpha-thalassemia usually die at the third trimester of pregnancy or soon after birth.

187 Supplementation with n-3 LCPUFA in the third trimester of pregnancy reduced the absolute risk o

188 m mother-infant pairs in Bangladesh from the third trimester of pregnancy to 72 weeks postpartum and

189 VE estimate for Tdap administered during the third trimester of pregnancy was 77.7% (95% confidence i

190 Antibiotic use in the third trimester of pregnancy was associated with a small

191 trol analysis, the use of antibiotics in the third trimester of pregnancy was associated with an incr

192 Prenatal exposure to NO2 in the third trimester of pregnancy was associated with higher

193 Rashes in the third trimester of pregnancy were associated with brain

194 iotic-fluid sample was from a patient in the third trimester of pregnancy who underwent amniocentesis

195 ial, we enrolled 2507 women in the second or third trimester of pregnancy who were planning to delive

196 Married women (aged 16-45 years) in their third trimester of pregnancy with perinatal depression w

197 al vaccine given in the late second or early third trimester of pregnancy would prevent most maternal

198 of viability for preterm birth encompass the third trimester of pregnancy, a "precritical period" of

199 e enrolled women who were in their second or third trimester of pregnancy, aged at least 15 years, an

200 ncy anemia (IDA) is relatively common in the third trimester of pregnancy, but causal associations wi

201 , a worker carried out one home visit in the third trimester of pregnancy, monthly visits to children

202 omly assigned to receive fish oil during the third trimester of pregnancy, olive oil, or no oil in th

203 In the third trimester of pregnancy, the human fetus has the ca

204 o were treated with natalizumab during their third trimester of pregnancy, we assessed the clinical a

205 que to pregnancy and primarily occurs in the third trimester of pregnancy, with a hallmark of elevate

206 llular pertussis vaccine were boosted in the third trimester of pregnancy.

207 al changes in the auditory system during the third trimester of pregnancy.

208 the target concentration (0.04 mg/L) in the third trimester of pregnancy.

209 ) were observed four times in the second and third trimester of pregnancy.

210 in the second trimester and to 51.2% in the third trimester of pregnancy.

211 mother smoking 4-5 cigarettes per day in the third trimester of pregnancy.

212 t underwent fetal MRI during their second or third trimester of pregnancy.

213 of omega-3-PUFA that normally occurs in the third trimester of pregnancy.

214 8%) control mothers received Tdap during the third trimester of pregnancy.

215 he Boston area gave stool samples during the third trimester of their pregnancy and answered question

216 of insulin resistance) during the second and third trimesters of pregnancy (r(s) </= -0.27, P < 0.05)

217 h 4400 IU/d vitamin D3 during the second and third trimesters of pregnancy by using a subset of cord

218 us to 1.5-T MR imaging during the second and third trimesters of pregnancy is not associated with an

219 ency questionnaire in the first, second, and third trimesters of pregnancy was 25%, 11%, and 10%, res

220 ldhood growth was measured during second and third trimesters of pregnancy, at birth, and at 6, 12, 2

221 ed across the placenta during the second and third trimesters of pregnancy.

222 requency questionnaires during the first and third trimesters of pregnancy.

223 al to reconstruct exposure in the second and third trimesters of prenatal development and during earl

224 muscle weakness resulted in death during the third trimester or shortly after birth.

225 cond trimester OR, 0.5; 95% CI, 0.2-1.2; and third trimester OR, 0.3; 95% CI, 0.1-1.2).

226 d PM2.5 was stronger for exposure during the third trimester (OR = 1.42 per IQR increase in PM2.5; 95

227 d trimester (OR = 1.67; 95% CI: 1.35, 2.08), third trimester (OR = 1.53; 95% CI: 1.24, 1.90), and who

228 those starting during the first, second, or third trimester (P < .001).

229 mRNA expression increased from the first to third trimester (P < 0.01), and the receptors localized

230 e monitoring (22.2%) were more common in the third trimester (P = .001).

231 e fms-like tyrosine kinase-1 (sFlt-1) in the third trimester (P<0.05), in the absence of preeclampsia

232 aternal characteristics affected second- and third-trimester placental resistance indices.

233 TTP presented primarily in the third trimester/postpartum, but fetal loss was highest i

234 Here we used PET and MRI and show that in third-trimester pregnant nonhuman primates, cocaine at d

235 Third-trimester pregnant women (>/=28 weeks' gestation)

236 PTH and 25(OH)D3 half-life were measured in third-trimester pregnant women (n22) and repeated during

237 Third-trimester pregnant women excreted less urinary fol

238 g/d) plus natural food folate (400 mug/d) in third-trimester pregnant women, lactating women 5-15 wk

239 -response choline feeding study conducted in third-trimester pregnant women, we investigated the effe

240 al heart rate, genotype, and phenotype; mean third trimester prelabor fetal heart rates obtained from

241 Primary outcomes were third-trimester preterm birth (27-36 weeks), birth weigh

242 with younger age, ART initiation during the third trimester, previous defaulting on ART, and postpar

243 elopmental period corresponding to the human third trimester regulates nAChR expression.

244 and 27.5% +/- 3.5% in the first, second, and third trimesters, respectively).

245 and 29.5 +/- 2.7% in the first, second, and third trimesters, respectively).

246 21%, 19%, and 29% in the first, second, and third trimesters, respectively, with high rates for the

247 ctomy were encountered in the second and the third trimesters, respectively.

248 intake) (mg/d) during the first, second, and third trimesters, respectively.

249 (33.3% vs. 14.3% and 10.5% in the second and third trimesters, respectively; P = 0.002).

250 with lower fetal length and weight growth in third trimester resulting in a smaller size at birth amo

251 First trimester sCD14 and LBP levels and third trimester sCD14 levels were significantly higher i

252 onachlor and oxychlordane levels measured in third-trimester serum from the mothers of 217 sons with

253 During the second and third trimesters, simultaneously enhanced estrogen level

254 An estimated 2.6 million third trimester stillbirths occurred in 2015 (uncertaint

255 rse pregnancy outcome, with nearly 3 million third-trimester stillbirths occurring worldwide each yea

256 Administration of alpha-GalCer in the third trimester suppressed PPARgamma activation, as show

257 binding protein-associated factor (TBP)] and third-trimester [Testis-expressed sequence 15 protein (T

258 At third trimester, the high TCS concentration was associat

259 during preconception; the first, second, and third trimesters; the entire period of pregnancy; and F2

260 centrations are suppressed in the second and third trimesters, thereby facilitating an increased supp

261 In utero delivery of this vector in the third trimester to fetal monkeys conferred expression of

262 axis is offered for 4 months starting in the third trimester to women with DNA load >/=10(6) copies/m

263 ed on human placentae from first, second and third trimesters to determine methylation patterns of ho

264 differential expression of XAF1 in first and third trimester trophoblast cells was due to changes in

265 expression and function of Nod1 and Nod2 in third-trimester trophoblasts, and to characterize the in

266 ndetected in control or Dex-treated cultured third-trimester trophoblasts.

267 Higher third trimester umbilical and uterine artery vascular re

268 Higher third trimester umbilical artery vascular resistance, bu

269 Third-trimester urinary biomarkers of oxidative/nitrativ

270 , 95% CI=0.40-1.77), or first-, second-, and third-trimester use (odds ratio=1.06, 95% CI=0.71-1.58).

271 , 95% CI=0.37-2.17), or first-, second-, and third-trimester use (odds ratio=1.27, 95% CI=0.82-1.99).

272 In the early third trimester, uterine blood flow was measured by Dopp

273 The geometric mean ratios for third-trimester versus postpartum maraviroc were 0.72 (9

274 Geometric mean ratios of third trimester vs postpartum were 0.55 (90% confidence

275 Mean temperature increase in the third trimester was 0.38 degrees C +/- 0.27, with no sig

276 10-ppb increase in ozone exposure during the third trimester was also associated with a slightly elev

277 n as a supplement in higher doses during the third trimester was associated with eczema, there was no

278 BANA-positive plaque in the third trimester was associated with preterm births after

279 of antidepressants during the second and/or third trimester was associated with the risk of ASD (31

280 ernal influenza vaccination in the second or third trimester was not associated with increased ASD ri

281 reuptake inhibitors during the second and/or third trimester was significantly associated with an inc

282 Overall, larger fetal size in the second and third trimesters was positively associated with childhoo

283 to PM2.5 during pregnancy, particularly the third trimester, was associated with greater odds of a c

284 ent of this possibility, greater second- and third-trimester weight gain beyond a threshold may be pr

285 d maternal levels of homocysteine during the third trimester were associated with adult schizophrenia

286 igher mean PM2.5 and BC exposures during the third trimester were associated with higher SBP (e.g., 1

287 pplications just before conception or during third trimester were at greater risk for both ASD and DD

288 Similarly, children exposed in the second or third trimester were not more likely to be hospitalized

289 r intake (C12h) plasma concentrations in the third trimester were on average 29% and 36% lower, respe

290 mothers vaccinated at the beginning of their third trimester were protected.

291 Pregnant women in their third trimester were screened for eligibility either dur

292 ic, 54% of pregnant women in their second or third trimester were vaccinated.

293 ients for correlation between the second and third trimesters were 0.50 and 0.32 for uterine artery r

294 Placental explants from first and third trimesters were challenged with 0.1 to 10 mug/mL L

295 were found for any trimester, including the third trimester, which is thought to be most relevant (T

296 otal of 3428 pregnant women in the second or third trimester who had falciparum malaria (at any paras

297 changes in dietary intake from the second to third trimester with emphasis on energy intake and carbo

298 ET/MR imaging), and 1 was scanned during the third trimester (with PET).

299 te during pregnancy, most notably during the third trimester, with a flare of disease activity 3-6 mo

300 O2) during the first, second, and cumulative third trimesters within 300 m of maternal address were e